SCHEMBL1269425

SCHEMBL1269425

CC1CCCCC(C)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.42
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
CA4 P22748 2/20 0.38
ACHE P22303 1/20 0.38
KMT2A Q03164 2/20 0.36
ALDH1A1 P00352 1/20 0.36
TDP1 Q9NUW8 2/20 0.33
TSHR P16473 2/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
NOS3 P29474 2/20 0.32
NOS1 P29475 2/20 0.32
NOS2 P35228 2/20 0.32
ESR2 Q92731 1/20 0.32
GAA P10253 1/20 0.32
PKM P14618 1/20 0.32
THRB P10828 1/20 0.31
MEN1 O00255 1/20 0.31
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31559147 1.00 EPHX1 (0.42) EPHX1CA1CA2CA4ACHE
SCHEMBL31746167 1.00 EPHX1 (0.42) EPHX1CA1CA2CA4ACHE
SCHEMBL1269311 0.96 EPHX1 (0.40) EPHX1CA1CA2CA4ACHE
SCHEMBL28354173 0.95 CA1 (0.40) EPHX1CA1CA2CA4ACHE
Methylcyclopentane SCHEMBL862 0.95
Cycloheptane SCHEMBL23885013 0.91 ACHE (0.43) EPHX1CA1CA2CA4ACHE
Methylcyclopentane SCHEMBL8234171 0.91
SCHEMBL5189 0.91
Cyclohexane SCHEMBL3670822 0.91 ACHE (0.43) EPHX1CA1CA2CA4ACHE
SCHEMBL15121491 0.91 ACHE (0.43) EPHX1CA1CA2CA4ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240344094-A1 METHODS AND COMPOSITIONS USEFUL FOR THE PRODUCTION OF OLEFINIC ESTER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-10-17 US claimed
US-20240158816-A1 METHODS AND COMPOSITIONS FOR THE PRODUCTION AND DEHYDRATION OF ISOPRENOL INTO ISOPRENE U.S. DEPARTMENT OF ENERGY 2024-05-16 US claimed
WO-2023077017-A1 METHODS AND COMPOSITIONS USEFUL FOR THE PRODUCTION OF OLEFINIC ESTER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-05-04 WO claimed
US-20260117135-A1 SYSTEMS AND METHODS FOR PRODUCING A DIMETHYLCYCLOOCTANE-BASED AVIATION FUEL FROM ISOPRENE CleanJoule, Inc. (US) 2026-04-30 US disclosed
US-20260092023-A1 PROCESS SYNTHESIZING SUSTAINABLE AVIATION FUEL COMPOSITIONS VISOLIS INC (US) 2026-04-02 US disclosed
US-20260092228-A1 COMPOSITIONS FOR FUEL BLENDING MADE BY A SUSTAINABLE PROCESS, AND SUSTAINABLE FUEL COMPOSITIONS THEREFROM VISOLIS INC (US) 2026-04-02 US disclosed
US-20260092130-A1 PROCESS FOR SYNTHESIZING POLYMER COMPOSITIONS FROM STARTING MATERIALS COMPRISING A DOUBLE BOND VISOLIS INC (US) 2026-04-02 US disclosed
US-20260062631-A1 CYCLOOCTANE CONTAINING FUEL COMPOSITIONS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 2026-03-05 US disclosed
US-20260028433-A1 PROCESS FOR SYNTHESIZING TACKIFYING COMPOSITIONS FROM STARTING MATERIALS COMPRISING A DOUBLE BOND VISOLIS INC (US) 2026-01-29 US disclosed
US-20260028545-A1 SUSTAINABLE AVIATION FUEL COMPOSITIONS VISOLIS INC (US) 2026-01-29 US disclosed
US-20260028539-A1 COMPOSITIONS FOR PRODUCTION OF OLEFINS, TERPENES, AROMATICS AND CYCLOALIPHATICS AND METHODS THEREFOR, AND PRODUCTS THEREFROM VISOLIS INC (US) 2026-01-29 US disclosed
EP-0823423-B1 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES BANYU PHARMA CO LTD (JP) 2004-06-16 EP disclosed
US-6140338-A FOR TREATING ACUTE INFLAMMATORY DISEASES, CHRONIC INFLAMMATORY DISEASES, ACQUIRED IMMUNE DEFICIENCY SYNDROME, CANCER, ISCHEMIC REFLOW DISORDER AND/OR ARTERIOSCLEROSIS BANYU PHARMACEUTICAL, CO., LTD. (JP) 2000-10-31 US disclosed
US-6040449-A USEFUL FOR FORMING FLUORINE CONTAINING 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES, USEFUL AS ANTAGONIST FOR MUSCARINIC M3 RECEPTORS AND LESS SIDE EFFECT BANYU PHARMACEUTICAL CO LTD (JP) 2000-03-21 US disclosed
US-5948792-A POTENT AND SELECTIVE ANTAGONISTS FOR MUSCARINIC M.SUB.3 RECEPTORS WITH LITTLE SIDE EFFECTS. BANYU PHARMACEUTICAL CO., LTD. (JP) 1999-09-07 US disclosed
EP-0930298-A1 FLUORINATED 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 1999-07-21 EP disclosed
EP-0916668-A1 CHEMOKINE RECEPTOR ANTAGONISTS BANYU PHARMACEUTICAL CO., LTD. (JP) 1999-05-19 EP disclosed
US-5750540-A SIDE EFFECT REDUCTION BANYU PHARMACEUTICAL CO., LTD. (JP) 1998-05-12 US disclosed
EP-0823423-A1 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 1998-02-11 EP disclosed
US-4739120-A RHODIUM CATALYST, BASIC SOLUTION OR IMMISCIBLE ORGANIC SOLVENT AND WATER THE DOW CHEMICAL COMPANY (US) 1988-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158816-A1 METHODS AND COMPOSITIONS FOR THE PRODUCTION AND DEHYDRATION OF ISOPRENOL INTO ISOPRENE MSMO1, DHCR7, ICMT EPHX1 355/4885CA1 1270/4885CA2 2116/4885
US-20260028433-A1 PROCESS FOR SYNTHESIZING TACKIFYING COMPOSITIONS FROM STARTING MATERIALS COMPRISING A DOUBLE BOND FZD7, WNT1, SFRP1 EPHX1 3463/4885CA1 2951/4885CA2 2943/4885
US-20260117135-A1 SYSTEMS AND METHODS FOR PRODUCING A DIMETHYLCYCLOOCTANE-BASED AVIATION FUEL FROM ISOPRENE ERG28, DIMT1, MSMO1 EPHX1 2741/4885CA1 1725/4885CA2 1069/4885
US-20260092228-A1 COMPOSITIONS FOR FUEL BLENDING MADE BY A SUSTAINABLE PROCESS, AND SUSTAINABLE FUEL COMPOSITIONS THEREFROM CYP4F12, CYP4F11, CYP4F8 EPHX1 960/4885CA1 2799/4885CA2 3036/4885
US-20260092023-A1 PROCESS SYNTHESIZING SUSTAINABLE AVIATION FUEL COMPOSITIONS CYP4A11, HMGCR, FADS1 EPHX1 841/4885CA1 2171/4885CA2 2831/4885
US-20260062631-A1 CYCLOOCTANE CONTAINING FUEL COMPOSITIONS CPT1A, CPT2, CNR2 EPHX1 1756/4885CA1 2071/4885CA2 1134/4885
US-20260092130-A1 PROCESS FOR SYNTHESIZING POLYMER COMPOSITIONS FROM STARTING MATERIALS COMPRISING A DOUBLE BOND SAMM50, MAX, HSF1 EPHX1 2088/4885CA1 3770/4885CA2 3259/4885
US-20260028539-A1 COMPOSITIONS FOR PRODUCTION OF OLEFINS, TERPENES, AROMATICS AND CYCLOALIPHATICS AND METHODS THEREFOR, AND PRODUCTS THEREFROM CYP4F11, FDFT1, CYP4A11 EPHX1 1037/4885CA1 2560/4885CA2 2989/4885
US-20260028545-A1 SUSTAINABLE AVIATION FUEL COMPOSITIONS CYP4F12, CYP4F11, CYP4F8 EPHX1 1718/4885CA1 1074/4885CA2 838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.